Drug induced QT prolongation;Medikamentös induzierte verlängerung des QT-intervalls

Wiener Klinische Wochenschrift

Volumn 120, Issue 5-6, 2008, Pages 128-135

  Altmann, David ^a   Eggmann, Urs ^b   Ammann, Peter ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Facharzt FMH für Allgemeinmedizin ^*  (Switzerland)

Author keywords

Cardiac arrhythmia; Drugs; Long QT syndrom; QT interval; Sudden cardiac death; Torsades de pointes

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; CLOMIPRAMINE; CLOZAPINE; CYCLOGUANIL; CYTOCHROME P450; DOXEPIN; DROPERIDOL; ELECTROLYTE; FEXOFENADINE; HALOPERIDOL; IBUTILIDE; IMIPRAMINE; MACROLIDE; MAGNESIUM; METHADONE; MIZOLASTINE; NEUROLEPTIC AGENT; OLANZAPINE; POTASSIUM CHANNEL BLOCKING AGENT; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SOTALOL; UNINDEXED DRUG;

ARTICLE; BRADYCARDIA; DEFIBRILLATION; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INHIBITION KINETICS; INTERNET; LONG QT SYNDROME; PRESCRIPTION; QT INTERVAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; SUDDEN DEATH; TORSADE DES POINTES;

CARDIAC PACING, ARTIFICIAL; DEATH, SUDDEN, CARDIAC; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HUMANS; INFUSIONS, INTRAVENOUS; LONG QT SYNDROME; MAGNESIUM; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 41749091855     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-0940-6     Document Type: Article

References (19)

1. Goldenberg I, Moss AJ, Zareba W (2006) QT-Interval: How to measure it and what is normal. J Cardiovasc Electrophysiol 17: 333-336
2. Indik JH, Pearson EC, Fried K, Woosley RL (2006) Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3: 1003-1007
3. Yap YG, Camm AJ (2003) Drug induced prolongation and torsades de pointes. Heart 89: 1363-1372
4. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channel and cardiac arrhythmia. Nature 440: 463-469
5. Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350: 1013-1022
6. Antzelevitch C (2005) Role of transmural dispersion of repolarization in the genesis of drug induced torsades de pointes. Heart Rhythm 2: 9-15
7. Yamaguchi M, Shimizu M, Ino H, terai H, Uchiyama K, Mabuchi T, et al (2003) T wave peak-to-end interval and QT dispersion in aquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 105: 671-676
8. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S (2003) Torades de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine 82: 282-290
9. Abi Gerges N, Philip K, Pollard C, Wakefield I, Hammond TG, Valentin JP (2004) Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de pointes. Fundam Clin Pharmacol 18: 139-151
10. Strohmer B, Schernthaner C, Iglseder B, Paulweber B, Pichler M (2007) Gender-specific effect of metabolic syndrome on rate adjusted QT interval in middle-aged participants of an atherosclerosis prevention program. Wien Klin Wochenschr 119: 544-552
11. Lethonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H (2007) Further evidence of inherited long QT syndrome gene mutations in antiarrhytmic drug-associated torsades de pointes. Heart Rhythm 4: 603-607
12. Nogales Asensio JM, Moreno Sanches N, Doncel Vecino LJ, Villar Mariscal C, Lopez-Minguez JR, Merchàn Herra A (2007) Torsade de pointes in a patient under flecainide treatement, an unusual case of proarrhythmicity. Int J Cardiol 114: E65-E67
13. Theverin J, Da Costa A, Roche F, Romeyer C, Messier M, Isaaz K (2003) Flecainid induced ventricular tachycardia (torsades de pointes). Pacing Clin Electrophysiol 26: 1907-1908
14. Glatter K, Yang Y, Chatterjee K, Modin G, Cheng J, Kayser S, et al (2001) Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy. Circulation 103: 253-257
15. Hekkala AM, Swan H, Väänänen H, Viitasalo M, Toivonen L (2007) The effect of antihistamine cetirizine on ventricular repolarisation in congenital long QT syndrome. J Cardiovasc Electrophysiol 18: 691-695
16. Strle F, Maraspin V (2002) Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 114: 396-399
17. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, et al (2002) Divergent proarrhythmic potential of macrolide antiobiotics despite similar QT prolongation: fast Phase 3 repolarization prevents early afterdepolarisations and torsade de pointes. J Pharmacol Exp Ther 303: 218-225
18. Sticherling C, Schaer BA, Ammann P, Maeder M, Osswald S (2005) Methadone induced Torsade de pointes tachycardias. Swiss Med Wkly 135: 282-285
19. Al-Kathib SM, Allen LaPointe NM, Kramer JM, Califf RB (2003) What clinicians should know about the QT interval. JAMA 289: 2120-2128